ArQule and Daiichi Sankyo Ink c-Met and Discovery Deals

ArQule and Daiichi Sankyo announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. One agreement covers the license of ARQ 197 and the other is an R&D agreement.
ARQ 197 is a phase 2 stage, selective inhibitor of c-Met, [...]

Genentech Drops The Other Shoe

We all knew it was just a matter of time until the “special committee” appointed to review the Roche officially rejected the buyout offer of $89/share.
The press release indicates a willingness to listen to offers that “recognizes the value of the company and reflects the significant benefits that would accrue” to an acquiring company.
Move along [...]

Roche on Spending Spree

First Roche offers to buy Genentech for ~$44B and in two consecutive days has inked two more deals.
Yesterday, in its second RNAi play in a year, Roche bought Mirus Bio for $125M. The acquisition should add value to the July 2007 preclinical discovery deal with RNAi leader Alnylam. Under the agreement, Mirus will [...]

Will Roche Kill Independent Genentech?

Roche has offered to buy the 45% stake of Genentech it doesn’t already own with a $89/share, $43.7B (8.8% premium) offer.
The initial Roche/Genentech deal brokered in the 90’s has been key to Roche’s success in the last few years. Upon first blush, this deal seems a natural fit and a no-brainer for Roche but [...]

ThromboGenics and BioInvent Ink Deal With Roche

Image via Wikipedia

BioInvent and ThromboGenics have entered into a license agreement with Roche for, TB-403, their novel mAb targeting Placental Growth Factor (PIGF) for the treatment of cancer. Under the terms of the agreement:
Roche will pay BioInvent and ThromboGenics an upfront payment of €50 million. In addition, BioInvent and ThromboGenics could potentially receive up to [...]